Rigosertib Phase 1 results lead to disease-focused Phase 2 development
Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This ...
Apr 9, 2013
0
0